+ Follow TIOTROPIUM Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 168699
[Title] => Breakthrough drug for COPD out
[Summary] => Two pharmaceutical companies, Boehringer Ingelheim and Pfizer, recently introduced Tiotropium, a novel drug that will provide remedy to patients suffering from Chronic Obstructive Pulmonary Disorder (COPD).
Tiotropium is the first once-daily inhaled therapy for the maintenance and treatment of COPD.
While it is less known than asthma, COPD is far more prevalent. World Health Organization (WHO) studies state that there are 600 million people suffering from COPD, although most remain undiagnosed.
[DatePublished] => 2002-07-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 136000
[Title] => Tiotropium effective for COPD — study
[Summary] => BERLIN, Germany — Tiotropium was shown effective in treating patients with chronic obstructive pulmonary disease (COPD), according to data from a long-term clinical trial presented here at the annual meeting of the European Respiratory Society.
Tiotropium, a once-daily inhaled anticholinergic, was found superior to the long-acting beta agonist salmeterol in several key aspects.
[DatePublished] => 2001-10-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 83568
[Title] => Benefits of inhaled therapy for COPD cited
[Summary] => SAN FRANCISCO – Data from 13 scientific presentations of Boehringer Ingelheim’s tiotropium, the first once-daily inhaled therapy being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), were presented at the 97th International Conference of the American Thoracic Society.
COPD is the world’s fourth leading cause of death with approximately three million people dying each year from the smoking-related respiratory illness.
[DatePublished] => 2001-06-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Real Estate
[SectionUrl] => real-estate
[URL] =>
)
)
)
TIOTROPIUM
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 168699
[Title] => Breakthrough drug for COPD out
[Summary] => Two pharmaceutical companies, Boehringer Ingelheim and Pfizer, recently introduced Tiotropium, a novel drug that will provide remedy to patients suffering from Chronic Obstructive Pulmonary Disorder (COPD).
Tiotropium is the first once-daily inhaled therapy for the maintenance and treatment of COPD.
While it is less known than asthma, COPD is far more prevalent. World Health Organization (WHO) studies state that there are 600 million people suffering from COPD, although most remain undiagnosed.
[DatePublished] => 2002-07-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 136000
[Title] => Tiotropium effective for COPD — study
[Summary] => BERLIN, Germany — Tiotropium was shown effective in treating patients with chronic obstructive pulmonary disease (COPD), according to data from a long-term clinical trial presented here at the annual meeting of the European Respiratory Society.
Tiotropium, a once-daily inhaled anticholinergic, was found superior to the long-acting beta agonist salmeterol in several key aspects.
[DatePublished] => 2001-10-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 83568
[Title] => Benefits of inhaled therapy for COPD cited
[Summary] => SAN FRANCISCO – Data from 13 scientific presentations of Boehringer Ingelheim’s tiotropium, the first once-daily inhaled therapy being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), were presented at the 97th International Conference of the American Thoracic Society.
COPD is the world’s fourth leading cause of death with approximately three million people dying each year from the smoking-related respiratory illness.
[DatePublished] => 2001-06-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Real Estate
[SectionUrl] => real-estate
[URL] =>
)
)
)
abtest
October 8, 2001 - 12:00am
